Loss of placental growth factor protects mice against vascular permeability in pathological conditions.

[1]  Lawrence A. Yannuzzi,et al.  PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.

[2]  L. Iversen,et al.  Heparin-binding protein (HBP/CAP37): A missing link in neutrophil-evoked alteration of vascular permeability , 2001, Nature Medicine.

[3]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[4]  P. Scheurich,et al.  A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. , 2001, Blood.

[5]  R K Jain,et al.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Michael Chopp,et al.  Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke , 2001, Nature Medicine.

[7]  G. Tosato,et al.  Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Primary Effusion Lymphomas , 2001, Leukemia & lymphoma.

[8]  J. Isner,et al.  Lower-Extremity Edema Associated with Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor , 2000, Annals of Internal Medicine.

[9]  R. Crystal,et al.  Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. , 2000, American journal of respiratory cell and molecular biology.

[10]  J. Wilson.  The bronchial microcirculation in asthma. , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  K Miyamoto,et al.  Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). , 2000, The American journal of pathology.

[12]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[13]  D. Fairlie,et al.  Cell phenotype as a target of drug therapy in chronic inflammatory diseases. , 2000, Medical hypotheses.

[14]  N. van Bruggen,et al.  VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. , 1999, The Journal of clinical investigation.

[15]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[16]  M. Marrero,et al.  Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src* , 1999, The Journal of Biological Chemistry.

[17]  R K Jain,et al.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.

[18]  R. Jain,et al.  Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. , 1999, Microvascular research.

[19]  M. Shibuya,et al.  A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain* , 1998, The Journal of Biological Chemistry.

[20]  N. Ferrara,et al.  Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. , 1998, The American journal of pathology.

[21]  Gustafsson,et al.  Allergen challenge‐induced extravasation of plasma in mouse airways , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[22]  R K Jain,et al.  Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. , 1998, The Journal of investigative dermatology.

[23]  K. Alitalo,et al.  A Recombinant Mutant Vascular Endothelial Growth Factor-C that Has Lost Vascular Endothelial Growth Factor Receptor-2 Binding, Activation, and Vascular Permeability Activities* , 1998, The Journal of Biological Chemistry.

[24]  I. Shiels,et al.  Vascular leakage stimulates phenotype alteration in ocular cells, contributing to the pathology of proliferative vitreoretinopathy. , 1998, Medical hypotheses.

[25]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. , 1998, Circulation.

[26]  E. Vitetta,et al.  Vascular leak syndrome: a side effect of immunotherapy. , 1997, Immunopharmacology.

[27]  Hidehiro Ishii,et al.  Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor , 1997, Diabetes.

[28]  L. Hinshaw,et al.  Sepsis/septic shock: participation of the microcirculation: an abbreviated review. , 1996, Critical care medicine.

[29]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[30]  J. Severinghaus.  Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. , 1995, Journal of applied physiology.

[31]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[32]  N. Mcclure,et al.  Image analysis quantification of the Miles assay. , 1994, Journal of pharmacological and toxicological methods.

[33]  M. Gentle,et al.  Neurogenic inflammation in the chicken (Gallus gallus var domesticus). , 1993, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[34]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[35]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Province,et al.  Modulation of Hemodynamic and Vascular Filtration Changes in Diabetic Rats by Dietary myo-inositol , 1990, Diabetes.

[37]  J. Casals-stenzel.  Effects of WEB 2086, a novel antagonist of platelet activating factor, in active and passive anaphylaxis. , 1987, Immunopharmacology.

[38]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[39]  F. Plum,et al.  Edema and Vascular Permeability in Cerebral Ischemia: Comparison Between Ischemic Neuronal Damage and Infarction , 1982, Journal of neuropathology and experimental neurology.

[40]  O. Matsuo,et al.  Analysis of fluid in capsules implanted into dog brain. , 1974, The Japanese journal of physiology.

[41]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[42]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[43]  A. Wilks,et al.  Placenta growth factor and vascular endothelial growth factor are co-expressed during early embryonic development. , 1997, Growth factors.

[44]  D. Maglione.  Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .